Display Single Record

FOI Request

Disclosure ID
FOI/06334
Request Date
October 5, 2023
Subject
Cancer treatment
Description

I would be very grateful if you could please answer these questions in relation to cancer treatment.

1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:
A) Metastatic Melanoma
B) Adjuvant Melanoma
C) BRAF mutated Lung Cancer

2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:
A) Metastatic Melanoma
B) Colorectal Cancer
C) Any other indications

Response

I would be very grateful if you could please answer these questions in relation to cancer treatment.

Data range covered is 01/04/2023 to 30/09/23 inclusive.

1) Over the last 6 months, how many patients were treated with a combination of Dabrafenib + Trametinib for the following diseases:

  1. A) Metastatic Melanoma – 0
  2. B) Adjuvant Melanoma – 0
  3. C) BRAF mutated Lung Cancer – 0*

 

* In the same period 1 patient was identified who received the drug combination outlined and had a referral of suspected lung cancer but no diagnosis of ‘BRAF mutated Lung Cancer’ specifically has been recorded for this patient on our reporting system. It is likely that this level of granularity would not be reportable.

 

2) Over the last 6 months, how many patients were treated with a combination of Encorafenib (Braftovi) + Binimetnib (Mektovi) for the following diseases:

  1. A) Metastatic Melanoma – 0
  2. B) Colorectal Cancer – 0
  3. C) Any other indications – 0
Attachment 1
Attachment 2
Attachment 3
Attachment 4
Attachment 5
Attachment 6
Attachment 7
Attachment 8
Attachment 9